Developping the next generation of studies in RCC
|
|
- Allen Singleton
- 6 years ago
- Views:
Transcription
1 Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France
2 Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche, Nektar, Acceleron, Cerulean, Eisai Excuses for all sponsors/investigators who will be criticized along my talk I will focus on mrcc
3 Where are we in clinical trials for mrcc? In clinical trial.gov: Around 150 studies in «RCC» No «strategic» studies except: NCT (Personalized Targeted Inhibitors Treatment in Renal Cell Cancer) Efficacy of PD 1 inhibitors (pembrolizumab monotherapy!) Several studies on immune therapy combined with radiotherapy Some phase I combination studies with PD1-PDL1 inhibitors: CB-839, Varlilumab (anti CD27 ), HBI 8000, CXCR4 antagonist (X4P-001), Vorinostat Some phase I combination with VEGF inhibitors: axitinib and TRC105, axitinib and dalantercept, anti CD27 and sunitinib
4 Where are we in clinical trials for mrcc? In clinical trial.gov: Around 100 studies in «RCC» No «strategic» studies except: NCT (Personalized Targeted Inhibitors Treatment in Renal Cell Cancer) Efficacy of PD 1 inhibitors (pembrolizumab monotherapy!) Several studies on immune therapy combined with radiotherapy Some phase I combination studies with PD1-PDL1 inhibitors: CB-839, Varlilumab (anti CD27 ), HBI 8000 Some phase I combination with VEGF inhibitors: axitinib and TRC105, axitinib and dalantercept, anti CD27 and sunitinib Some phase 3
5 Some important phase 3 on pure immunotherapy Vaccine+ VEGFR inhibition PD1 + CTLA4 inhibition ADAPT 3 Phase III CheckMate Phase III Sunitinib Sunitinib 50 mg/day 4/2 R N = 450 AGS sunitinib 8 injections in first year followed by quarterly boosters + sunitinib R N = 1071 Nivolumab + ipilimumab 3 mg/kg IV + 1 mg/kg IV every 3 weeks 4 then nivolumab 3 mg/kg IV every 2 weeks Primary endpoint: OS Co-primary endpoint: PFS, OS
6 Some important phase 3 on VEGF + PD1/PDL1 inhibition PD-L1 + VEGF inhibition PD1 + VEGFR TK inhibition Javelin renal Phase III Immotion Phase III Lenvatinib + everolimus or pembrolizumab 3 Phase III KEYNOTE Phase III Sunitinib 50 mg/day 4/2 Sunitinib 50 mg/day 4/2 Sunitinib 50 mg/day 4/2 Sunitinib 50 mg/day 4/2 R N = 583 R N = 830 R N = 735 R N = 840 Avelumab + axitinib 10 mg/kg IV every 2 weeks + 5 mg PO BD Atezolizumab + bevacizumab 1,200 mg IV + 15 mg/kg IV every 3 weeks Lenvatinib + pembro 20 mg/day mg (IV) every 3 weeks Axitinib + pembro 5 mg BID mg (IV) every 3 weeks Lenvatinib + everolimus 18 mg/day + 5 mg/day Primary endpoint: PFS Co-primary endpoint: PFS, OS Primary endpoint: PFS Co-primary endpoint: PFS, OS
7 But all of them without the good control arm 1. Nobody still uses sunitinib 4/2 schedule without dose adaptation
8 RAINBOW Study: Efficacy Data 1 Patients, n Group 4/2 2/1 Group 2/1 Control with 50 mg on 2/1 102 with <50 mg on 2/ Median treatment duration, mo (interquartile range) 28.2 ( ) 7.8 ( ) 9.7 ( ) mpfs, mo (interquartile range) 30.2 ( ) 10.4 ( ) 9.7 ( ) mos, mo NR (36-mo probability: 72.7%) 23.2 (10.6 NE) 27.8 ( ) Patients in the 2/1 group had less favorable characteristics in terms of ECOG PS and the presence of brain metastases. 1. Bracarda S, et al. Ann Oncol, 2015.
9 But all of them without the good control arm 1. Nobody still uses sunitinib 4/2 schedule without dose adaptation 2. Axitinib first line is likely superior to sunitinib, so how to interprete Javelin 101 and Keynote 426, if axitinib + PD1/PDL-1 is superior to sunitinib
10 Objective response rate (%) Study 1046: Axitinib Objective Response Rate % (95% CI: 42 55) 54% (95% CI: 40 67) P=0.019* 34% (95% CI: 22 48) 59% (95% CI: 49 70) 20 0 Total (N=213 ) Axitinib titration (N=56) Placebo titration (N=56) Non-randomized (N=91) Rini BI, et al. Lancet Oncol 2013;14:
11 But all of them without the good control arm 1. Nobody still uses sunitinib 4/2 schedule without dose adaptation 2. Axitinib first line is likely superior to sunitinib, so how to interprete Javelin 101 and Keynote 426, if axitinib + PD1/PDL-1 is superior to sunitinib 3. Cabozantinib is probably superior to sunitinib
12 Progression-Free Survival (probability) Cabosun PFS (Choueiri et al, ESMO LBA 2016) Cabozantinib Sunitinib Time since randomization (months) Arm PFS Events Median PFS (95% CI), mo HR (95% CI)* Cabozantinib Sunitinib (6.2, 9.0) 5.6 (3.4, 8.1) 0.69 ( ) p-value (one-sided) = 0.012
13 Where are we in clinical trials for mrcc? In clinical trial.gov: Around 100 studies in «RCC» No «strategic» studies except: NCT (Personalized Targeted Inhibitors Treatment in Renal Cell Cancer) None of the studies, I would like to see!!!!! Except the SURF study (Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma: NCT )
14 SURF study ENROLLING FRANCE PI: Prof. A Thierry Vuillemin Inclusion: -mrcc -clear cell -Sunitinib 50mg/d 4 / 2 n = 248 patients # when dose adaptation required R A N D O M I S A T I O N 1:1 Arm A Sunitinib 37,5 mg 4 /2 Arm B Sunitinib 50 mg 2 /3
15 Where are we in clinical trials for mrcc? In clinical trial.gov: Around 100 studies in «RCC» No «strategic» studies except: NCT (Personalized Targeted Inhibitors Treatment in Renal Cell Cancer) None of the studies, I would like to see!!!!! Except the SURF study (Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma: NCT ) The TITAN study (NCT ): Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)
16 Tailored ImmunoTherapy Approach with Nivolumab in RCC n=200 Key Inclusion Criteria Metastatic/locally advanced RCC Clear cell component Untreated or pretreated with 1 prior TKI (1 st or 2 nd line) Measurable disease as per RECIST v1.1 ECOG PS 0-1 Intermediate/high risk by IDMC Nivo Induction Nivolumab 3 mg/kg IV Q2W x 8 Strata: -1 st vs. 2 nd Line -IMDC risk group (RCC TITAN; phase II) CR/PR SD/PD CR/PR Ipi Boost 1 Nivolumab 3 mg/kg IV Ipilimumab 1 mg/kg IV Q3W x 2 Nivo Maintenance Nivolumab 3 mg/kg IV Q2W SD/PD CR/PR/SD Ipi Boost 2 Nivolumab 3 mg/kg IV Ipilimumab 1 mg/kg IV Q3W x 2 Planned start Date: 12/2016 No. of sites: multi-national (GE, UK, F, I, E, P, Cz, Hungary, PL tbd) Study Director: Prof. Dr. Marc-Oliver Grimm Primary Endpoint: Objective response rate Secondary Endpoints: OS, ORR, PFS after boost, Safety, QoL Exploratory Endpoints: Biomarker analysis PD* *At time of PD after initial response: Boost/Re-boost with additional Ipilimumab (2/4 cycles according to the schedule above) possible for patients with CR, PR or SD for 3 months, no irae requiring treatment discontinuation
17 What is the next generation of clinical trials? The one which answers key questions Not the one which develops a new PD1 or PDL1 inhibitor. Not the one which adds to the current standard of care a drug which is supposed to improve PFS by 30%...
18 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors? 4. Should we treat beyond progression? 5. How to treat PD1 failure? 6. In second line, should we use cabozantinib or nivolumab? 7. How to treat rare RCC tumors? 8. Cytoreductive nephrectomy
19 What are the key questions? 1. How to get CR and cure patients? Just do small combination trials with the primary endpoint being CR rate Will be small studies With rapid readout
20 Phase 1/2 Combination of MBG453 (anti-tim-3) and PDR001 (Anti-PD-1) Phase 1/1b: Dose finding MBG453 Phase II: Advanced solid tumours, based on anti-tumour activity during phase 1 dose escalation Patients with advanced solid tumours RCC (n = 30) Group 1: Naïve to anti-pd-1/pd-l1 Group 2: Pre-treated with anti-pd-1/pd-l1 MBG453 + PDR001 Primary endpoints: Safety and tolerability ORR DLTs Melanoma (n = 30) NSCLC (n = 30) Group 3: Naïve to anti-pd-1/pd-l1 Group 4: Pre-treated with anti-pd-1/pd-l1 Group 5: Naïve to anti-pd-1/pd-l1 Group 6: Pre-treated with anti-pd-1/pd-l1 Completion: November 2018 Clinicaltrials.gov Identifier: NCT
21 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients?
22 Genomic classification of RCC ccrcc1 ccrcc2 ccrcc3+nl ccrcc4 Beuselinck et al. Clin Cancer Res Mar 15;21(6):
23 How to use such genomic classification? 12M 24M 24.5M 8M 22M 35M 50M 14M Beuselinck et al. Clin Cancer Res Mar 15;21(6):
24 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors?
25 Get back to randomisation discontinuation trial! Response assessment Tumour shrinkage 25% Sorafenib 400mg b.i.d. open-label Sorafenib 400mg b.i.d. 12-week run-in Tumour growth/ shrinkage <25% Sorafenib 400mg b.i.d. 12 weeks Placebo * 12 weeks Progression free at 24 weeks (%) Tumour growth 25% Off study * Patients who progressed on placebo could cross over to sorafenib Ratain MJ, et al. J Clin Oncol 2006;24:
26 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors? 4. Should we treat beyond progression? 5. How to treat PD1 failure?
27 New trial Response assessment SD or PR NIVOLUMAB Until PD or CR Placebo Until PD or CR NIVOLUMAB 3 months PD good PS NIVOLUMAB beyond progression Placebo 12 weeks TTF endpoint Rapid PD ADD ANOTHER CHECKPOINT
28 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors? 4. Should we treat beyond progression? 5. How to treat PD1 failure? 6. In second line, should we use cabozantinib or nivolumab?
29 Who will run this trial? Second-line mrcc TKI failures R A N D O M I Z E CABOZANTINIB NIVOLUMAB
30 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors? 4. Should we treat beyond progression? 5. How to treat PD1 failure? 6. In second line, should we use cabozantinib or nivolumab? 7. How to treat rare RCC tumors?
31 No more nccrcc trials such as this one! Everolimus n=35 Sunitinib n=33 Age (median, range) 58 (23-73) 60 (28-76) 0.72 Gender (M:F) 24:11 19: Nephrectomy Histology Papillary Sarcomatoid w/ clear-cell Chromophobe Unclassified Translocation P-value 0.97 Tannir N, et al. Eur Urol. 2016;69(5):
32 But trials such as CREATE trial Screened pts PRCC1 per local pathology N=41 PRCC1 analysis set Centrally confirmed PRCC1 and enrolled N=23 (all started crizotinib) MET+ N=4 MET+ analysis set Eligible and evaluable, N=4 Incl. 1 MET amplified MET- N=16 Eligible and evaluable, N=16 Incl. 1 MET amplified MET? N=3 Eligible and evaluable, N=3
33 Number of patients But with challenges Studies should be very multicentric Logistic should be simplified Registry should be favored Cost should be decreased Screened Eligible and treated Time
34 What are the key questions? 1. How to get CR and cure patients? 2. How to use «immunoscores» to select patients? 3. How long should we treat with PD1/PDL-1 inhibitors? 4. Should we treat beyond progression? 5. How to treat PD1 failure? 6. In second line, should we use cabozantinib or nivolumab? 7. How to treat rare RCC tumors? 8. Cytoreductive nephrectomy
35 We should not replicate Carmena trial for each new drug or regimen But focus on patients which raise the real question Not poor risk patients Not good risk patients with small metastatic burden But the one with good PS and metastatic tumor burden > 20-30% of the tumor burden..
36 Conclusions It is obviously time for new generation of clinical trials in RCC It is our responsibility to run GOOD trials which will answer important questions We should find a way to avoid «me too» trials
37 This is the role of all of us
Current experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationAlternativas de Futuro en Cáncer Renal Enrique Grande
Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s:
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationClinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin et al. Journal for ImmunoTherapy of Cancer (2018) 6:9 DOI 10.1186/s40425-018-0319-9 RESEARCH ARTICLE Open Access Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More information17th ESO-ESMO Masterclass Clinical Oncology
Metastatic Renal Cell Cancer: Evidence Based Treatment Manuela Schmidinger Medical University of Vienna, Austria Disclosures Honoraria for lectures or advisory boards from: Pfizer, Roche, BMS, Novartis,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationImmunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology 2013: Breakthrough of the Year December 20, 2013 Why immunotherapy? Immune
More information